Well Lead Medical Co., Ltd. (SHA:603309)

Market Cap	3.70B +8.8%
Revenue (ttm)	1.64B +5.9%
Net Income	77.35M -66.1%
EPS	0.27 -66.0%
Shares Out	291.87M
PE Ratio	47.75
Forward PE	11.74
Dividend	0.60 (4.73%)
Ex-Dividend Date	May 28, 2026

Volume	2,842,000
Open	12.42
Previous Close	12.68
Day's Range	12.27 - 12.54
52-Week Range	11.83 - 16.42
Beta	-0.17
Analysts	Buy
Price Target	n/a
Earnings Date	Jul 24, 2026

About Well Lead Medical

Well Lead Medical Co., Ltd. engages in the development, production, and sale of medical devices in urology, endourology, anaesthesia, respiratory, hemodialysis, and pain management areas worldwide. It provides urology products, including Foley catheter, Nelaton catheters, urine collection products, and accessories; endourology products, such as the ClearPetra family system, ureterorenoscope, guide wires, ureteral stent, urethral and ureteral dilation, and stone retrieval basket; anesthesia products, comprising endotracheal tubes, intubation acc...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1998
• Employees: 2,849
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603309

Financial Performance

In 2025, Well Lead Medical's revenue was 1.63 billion, an increase of 8.07% compared to the previous year's 1.51 billion. Earnings were 76.33 million, a decrease of -65.21%.